Table 1.

Clinical characteristics of patients included in the training and validation set.

	Training set (n = 79)	Validation set (n = 135)	p
Demographics
Gender
Male, n (%)	52 (65.8%)	102 (75.6%)	0.138
Age, years
Median (range)	68 (42–80)	67 (36–83)	0.205
Race, n (%)
Caucasian	72 (91%)	102 (75.6%)	0.001
African-American	3 (4%)	4 (3%)
Asian	4 (5%)	28 (20.7%)
Etiology of cirrhosis, n (%)			<0.001
Hepatitis C	79 (100.0)	54 (40.0)
Hepatitis B		45 (33.3)
Alcohol		9 (6.7)
Others		24 (17.8)
Tumor features
Tumor diameter, cm
Median (IQR)	3.5 (2.5–5.6)	3.5 (2.3–5)	0.234
>3 cm, n (%)	42 (53.2)	75 (55.6)	0.737
Tumor number, n (%)
Single (≤3 cm)	32 (40.5)	50 (37.0)
Single (>3 cm)	35 (44.3)
Multiple	12 (15.2)	18 (13.3)	0.727
Vascular invasion, n (%)	45 (57.0)	40 (29.6)	<0.001
Microvascular	37 (82.0)	40 (100.0)
Macrovascular	8 (18.0)	0 (0.0)
Blood test
Platelets (×1000/ml)	156 (131–179)	160 (120–209)	0.44
Bilirubin (mg/dl)	0.8 (0.6–1.1)	0.8 (0.6–1.1)	0.347
Albumin (g/dl)	4.1 (3.6–4.4)	4 (3.8–4.4)	0.904
Alpha-fetoprotein, n (%)
<10 mg/dl	25 (35%)	53 (41.4%)	0.70
10–100 mg/dl	26 (36.1%)	41 (32%)	0.02
>100 mg/dl	34 (47.2%)	21 (16.4%)	0.28
Events
Recurrence	43 (54.4%)	80 (59.3%)	0.560
Early Recurrence	32 (40.5%)	60 (44.4%)	0.629
Deaths	23 (29%)	32 (23.7%)	0.393
Median Follow up (months)	21 (13–42)	34 (25–47)	0.011